In Section A, participants will obtain unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled for the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase C, https://abbv-744-in-acute-myeloid13591.gynoblog.com/31306329/considerations-to-know-about-abbv-744-brd4-inhibitor-cancer-therapy-efficacy